Imugene share price leaps 5% on trial news

Imugene shares are starting the week on a positive note.

| More on:
Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Imugene shares climb 4.54% to 23 cents during mid-morning trade 
  • The company announced it received a DIR licence for its cancer-killing virus, Vaxinia 
  • This will allow Imugene to expand its Vaxinia phase 1 clinical trial within Australia 

The Imugene Limited (ASX: IMU) share price is shooting higher on Monday morning.

At the time of writing, Imugene shares are up 4.54% to 23 cents.

What's driving Imugene shares higher?

Investors are bidding up the Imugene share price after the company advised it received a DIR licence for its novel cancer-killing virus, CF33-hNIS (Vaxinia).

Granted by the Australian Government's Office of the Gene Technology Regulator (OGTR), the licence allows Imugene to expand its Vaxinia phase 1 clinical trial within Australia.

A DIR is a dealing involving the intentional release of genetically modified organisms (GMOs). The regulator sets out the conditions under which such dealings must be undertaken when a DIR licence is approved.

In May 2022, Imugene's Vaxinia trial commenced across the US, delivering a low dose of CF33-hNIS to patients with metastatic or advanced solid tumours and who had at least two prior lines of standard of care treatment.

The oncolytic virus, developed by City of Hope, has shown to shrink solid tumours in preclinical laboratory and animal trials.

These tumours include colon, lung, breast, ovarian and pancreatic cancers.

City of Hope is one of the largest cancer research and treatment organizations in the United States.

The study aims to recruit 100 patients across approximately 10 sites in the United States and Australia.

The trial is anticipated to run for approximately 24 months and will be funded from Imugene's existing cash reserves.

Commenting on being granted the licence, Imugene managing director and CEO, Leslie Chong said:

We're pleased to see this regulatory hurdle cleared on schedule which will allow the smooth progression of our VAXINIA Phase 1 trial as planned.

Imugene share price summary

Despite today's gain, it has been a disappointing 12 months for Imugene investors, with the company's share price falling more than 50%.

Imugene presides a market capitalisation of approximately $1.29 billion.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 9 January 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Medical or healthcare workers grasp hands in the universal expression of teamwork
Healthcare Shares

Here's how the ASX 200 market sectors stacked up last week

Healthcare was the strongest sector last week, with market darling Pro Medicus surging yet again.

Read more »

Three happy girls on jumping motion with inflatable mattresses at the beach.
Share Gainers

3 ASX All Ords shares leading the charge in 2025

These ASX All Ords shares have soared 16% to 37% already in 2025.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

3 ASX 200 healthcare stocks with 'strong return potential' in 2025

A leading investment manager expects 2025 will be a good year for these ASX 200 healthcare companies.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Why are Mesoblast shares in a trading halt?

The biotech company requested a trading halt before the market open on Friday. Here's why.

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

ASX All Ords stock rockets 18% on FDA clearance

This stock is making very healthy returns on US news.

Read more »

rising medical asx share price represented by excited doctors dancing in ward
Healthcare Shares

Up 77% in a month! What's going on with the Mesoblast share price?

This stock has blown the lights out in recent weeks...

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Guess which ASX healthcare stock is up 31% on big news

What is getting investors excited on Tuesday? Let's find out.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

Healthy gains: 5 best ASX 200 healthcare shares of 2024

Four of the five best-performing ASX 200 healthcare stocks of 2024 more than doubled in value.

Read more »